Fuller & Thaler Asset Management Inc. Has $43.08 Million Stock Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Fuller & Thaler Asset Management Inc. raised its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 232,388 shares of the company's stock after acquiring an additional 17,294 shares during the period. Fuller & Thaler Asset Management Inc. owned approximately 0.78% of Inspire Medical Systems worth $43,080,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its holdings in shares of Inspire Medical Systems by 178.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 357 shares of the company's stock worth $66,000 after acquiring an additional 229 shares during the period. Merit Financial Group LLC acquired a new stake in shares of Inspire Medical Systems in the 4th quarter worth approximately $313,000. Jennison Associates LLC acquired a new stake in shares of Inspire Medical Systems in the 4th quarter worth approximately $8,821,000. Janney Montgomery Scott LLC grew its holdings in shares of Inspire Medical Systems by 248.5% in the 4th quarter. Janney Montgomery Scott LLC now owns 4,806 shares of the company's stock worth $891,000 after acquiring an additional 3,427 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Inspire Medical Systems in the 4th quarter worth approximately $292,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the sale, the chief technology officer now directly owns 10,424 shares of the company's stock, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the sale, the insider now directly owns 7,259 shares in the company, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.10% of the company's stock.

Inspire Medical Systems Trading Up 0.8 %

INSP stock traded up $1.23 on Tuesday, hitting $159.34. 137,315 shares of the company's stock traded hands, compared to its average volume of 580,692. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $257.40. The stock has a market cap of $4.74 billion, a price-to-earnings ratio of 91.82, a P/E/G ratio of 2.86 and a beta of 1.39. The stock has a fifty day moving average of $162.45 and a 200-day moving average of $180.71.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. On average, equities research analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

INSP has been the subject of several analyst reports. Wells Fargo & Company cut their target price on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. Royal Bank of Canada decreased their target price on Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating for the company in a report on Tuesday, April 15th. Morgan Stanley decreased their target price on Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating for the company in a report on Tuesday, February 11th. Stifel Nicolaus decreased their price target on Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating for the company in a report on Monday, April 21st. Finally, Robert W. Baird decreased their price target on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating for the company in a report on Tuesday, February 11th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $218.90.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.